A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer Clinical Trial

Official title:

A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06111274
• Other study ID #: ABSK021-202
• Status: Recruiting
• Phase: Phase 2
• Start date: October 17, 2023
• Est. completion date: December 29, 2026

Study information

• Verified date: April 2024
• Source: Abbisko Therapeutics Co, Ltd
• Contact: YUAN LU
• Phone: +86-21-68910052
• Email: clinical[@]abbisko.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Complete the study procedures specified in the protocol, which is guided by researchers.

Description:

This is a phase II, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: December 29, 2026
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.
• Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.
• Measurable disease as defined by RECIST 1.1.
• Without systemic treatment for pancreatic cancer.
• ECOG physical strength score 0-2
• Estimated survival time >=3 months.
• The adequate bone marrow fuction and coagulation function

Exclusion Criteria:

• Known allergy or hypersensitivity to any components of the investigational drug product.
• Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
• With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
• With a history of other malignancies within 5 years.
• During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
• With conditions that significantly affected the absorption of oral drug.
• Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
• During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.
• Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.
• Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).
• Diagnosed with immune deficiency or interstitial lung disease.
• The patients were vaccinated within 4 weeks before the first treatment.
• Participated in any drug clinical trial within 4 weeks before the first treatment.
• Active central nervous system (CNS) metastases.
• Impaired cardiac function or clinically significant cardiac disease.
• Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
• Known active infections from certain viruses, bacteria or parasites.
• Patients with refractory/uncontrolled ascites or pleural effusion.
• Pregnant or lactating women.
• Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.

Related Conditions & MeSH terms

• Advanced Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Pimicotinib (ABSK021)
The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.

Locations

Country	Name	City	State
China	West China Hospital of Sichuan University	Chengdu
China	Harbin Medical University Cancer Hospital	Ha'erbin
China	Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Shanghai East Hospital Tongji University	Shanghai
China	Union Hospital Tongji Medical College Huazhong University of science and technolog	Wuhan

Sponsors (1)

Lead Sponsor	Collaborator
Abbisko Therapeutics Co, Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Event Occurance	The Number of Participants With Adverse Event (AE), a Serious Adverse Event (SAE) and Dose Limiting Toxicities (DLT) Event.	From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days)
Primary	Objective Response Rate (ORR)	The Percentage of Participants with confirmed Complete Response and Partial Response, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	Duration of Response	Duration of response (DOR) is defined as the time from the date of the first documentation of confirmed response (Complete Response or Partial Response) to the first objective documentation of progressive disease (PD) per RECIST v1.1 per Investigator assessment, or to death due to any cause in the absence of documented PD.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	Progression Free Survival	Progression-free survival (PFS) was defined as as the time from the first dose to the first objectively documented disease progression per RECIST v1.1 per Investigator assessment, or death due to any cause in the absence of documented progressive disease (PD). PFS was analyzed using Kaplan-Meier methods.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	Overall Survival	Overall survival (OS) was defined as the time from first dose of study drug to death due to any cause. OS was calculated using the Kaplan-Meier method.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	The exposure of ABSK021	The Area Under the Concentration Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Normalized by Dose.	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	The Maximum Concentration of ABSK021	Maximum Observed Concentration (Cmax)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Secondary	The Minimum Concentration of ABSK021	Minimum Observed Concentration (Cmin)	From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)